Clinical trial
BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the…
NCT00123916 · Population Health Research Institute, Other · Completed
Key facts
| NCT number | NCT00123916 |
|---|---|
| Title | BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease |
| Official title | Benznidazole Evaluation for Interrupting Trypanosomiasis - The BENEFIT Trial |
| Acronym | BENEFIT |
| Lead sponsor | Population Health Research Institute, Other |
| Collaborators | Canadian Institutes of Health Research (CIHR) World Health Organization Instituto Dante Pazzanese de Cardiologia University of Sao Paulo |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chagas Disease, Trypanosomiasis, Heart Disease |
| Intervention type | Drug |
| Interventions | Benznidazole, Placebo |
| Enrollment | 2,854 |
| Start date | Nov 1, 2004 |
| Primary completion | Jul 1, 2015 |
| Completion | Aug 1, 2015 |
| First posted | Jul 26, 2005 |
| Last update posted | Mar 3, 2020 |
| Countries | Argentina, Bolivia, Brazil, Colombia, El Salvador |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: